Table 1.
Baseline Covariates Before and After Matching
| Variables | Level | Before Matching | After Matching | ||||
|---|---|---|---|---|---|---|---|
| S+L (n=105) | RT+S+L (n=39) | SMD | S+L (n=38) | RT+S+L (n=38) | SMD | ||
| Age (%) | ≤ 60 | 72 (68.6) | 28 (71.8) | 0.072 | 29 (76.3) | 27 (71.1) | −0.117 |
| ˃ 60 | 33 (31.4) | 11 (28.2) | −0.072 | 9 (23.7) | 11 (28.9) | 0.117 | |
| Sex (%) | Female | 18 (17.1) | 7 (17.9) | 0.021 | 10 (26.3) | 7 (18.4) | −0.206 |
| Male | 87 (82.9) | 32 (82.1) | −0.021 | 28 (73.7) | 31 (81.6) | 0.206 | |
| Albumin (%) | ≤ 35 | 23 (21.9) | 5 (12.8) | −0.272 | 6 (15.8) | 5 (13.2) | −0.079 |
| ˃ 35 | 82 (78.1) | 34 (87.2) | 0.272 | 32 (84.2) | 33 (86.8) | 0.079 | |
| HBsAg (%) | Negative | 32 (30.5) | 11 (28.2) | −0.050 | 13 (34.2) | 11 (28.9) | −0.117 |
| Positive | 73 (69.5) | 28 (71.8) | 0.050 | 25 (65.8) | 27 (71.1) | 0.117 | |
| AFP.ng.mL (%) | ≤ 400 | 49 (46.7) | 13 (33.3) | −0.283 | 11 (28.9) | 13 (34.2) | 0.112 |
| ˃ 400 | 56 (53.3) | 26 (66.7) | 0.283 | 27 (71.1) | 25 (65.8) | −0.112 | |
| Alanine aminotransferase (%) | ≤ 44 | 81 (77.1) | 30 (76.9) | −0.005 | 29 (76.3) | 30 (78.9) | 0.062 |
| ˃ 44 | 24 (22.9) | 9 (23.1) | 0.005 | 9 (23.7) | 8 (21.1) | −0.062 | |
| Total bilirubin (%) | ≤ 17.1 | 57 (54.3) | 21 (53.8) | −0.009 | 24 (63.2) | 21 (55.3) | −0.158 |
| ˃ 17.1 | 48 (45.7) | 18 (46.2) | 0.009 | 14 (36.8) | 17 (44.7) | 0.158 | |
| Platelet (%) | ≤ 100 | 13 (12.4) | 4 (10.3) | −0.070 | 4 (10.5) | 4 (10.5) | 0.000 |
| ˃ 100 | 92 (87.6) | 35 (89.7) | 0.070 | 34 (89.5) | 34 (89.5) | 0.000 | |
| Tumor number (%) | Multiple | 54 (51.4) | 16 (41.0) | −0.211 | 14 (36.8) | 16 (42.1) | 0.107 |
| Single | 51 (48.6) | 23 (59.0) | 0.211 | 24 (63.2) | 22 (57.9) | −0.107 | |
| Maximum tumor diameter (%) | ≤ 5 | 45 (42.9) | 22 (56.4) | 0.273 | 22 (57.9) | 21 (55.3) | −0.053 |
| ˃ 5 | 60 (57.1) | 17 (43.6) | −0.273 | 16 (42.1) | 17 (44.7) | 0.053 | |
| Number of lung metastatic lesions (%) | 1 | 36 (34.3) | 8 (20.5) | −0.341 | 5 (13.2) | 8 (21.1) | 0.196 |
| 2 | 9 (8.6) | 5 (12.8) | 0.127 | 7 (18.4) | 5 (13.2) | −0.157 | |
| 3 | 4 (3.8) | 2 (5.1) | 0.060 | 1 (2.6) | 2 (5.3) | 0.119 | |
| ˃3 | 56 (53.3) | 24 (61.5) | 0.169 | 25 (65.8) | 23 (60.5) | −0.108 | |
| PVTT (%) | With | 43 (41.0) | 16 (41.0) | 0.001 | 17 (44.7) | 16 (42.1) | −0.054 |
| Without | 62 (59.0) | 23 (59.0) | −0.001 | 21 (55.3) | 22 (57.9) | 0.054 | |
| Child-Pugh classification (%) | A5 | 54 (51.4) | 25 (64.1) | 0.264 | 21 (55.3) | 24 (63.2) | 0.165 |
| A6 | 41 (39.0) | 12 (30.8) | −0.179 | 14 (36.8) | 12 (31.6) | −0.114 | |
| B7 | 10 (9.5) | 2 (5.1) | −0.199 | 3 (7.9) | 2 (5.3) | −0.119 | |
| ECOG performance status score (%) | 0 | 83 (79.0) | 24 (61.5) | −0.360 | 26 (68.4) | 24 (63.2) | −0.108 |
| 1 | 22 (21.0) | 15 (38.5) | 0.360 | 12 (31.6) | 14 (36.8) | 0.108 | |
| Other extrahepatic spread (%) | Bone | 11 (10.5) | 4 (10.3) | −0.007 | 5 (13.2) | 4 (10.5) | −0.087 |
| Lymph node | 18 (17.1) | 8 (20.5) | 0.083 | 8 (21.1) | 7 (18.4) | −0.065 | |
| None | 76 (72.4) | 27 (69.2) | −0.068 | 25 (65.8) | 27 (71.1) | 0.114 | |
Abbreviations: RT+S+L, radiotherapy combine with sintilimab plus lenvatinib; S+L, sintilimab plus lenvatinib; SMD, Standardized Mean Difference; HBsAg, hepatitis B surface antigen; AFP, alpha fetoprotein; ECOG, Eastern Cooperative Oncology Group; PVTT, portal vein tumor thrombus.